{"product_id":"molecules-engineered-against-oncogenic-proteins-and-cancer-discovery-design-and-development-9781394207084","title":"Molecules Engineered Against Oncogenic Proteins and Cancer: Discovery, Design, and Development","description":"\u003cb\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/b\u003e \u003cp\u003e\u003cb\u003eA comprehensive review of the latest molecular advances in cancer treatment\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eFeaturing 91 total small molecule kinase\/KRAS inhibitors, 80 of which are FDA-approved, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/i\u003e documents the recent scientific advances that have transformed one of medicine's most challenging areas--cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase\/KRAS inhibitors in clinical trials are presented. \u003c\/p\u003e\u003cp\u003eWith a very well-known chemist as an author, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/i\u003e includes information on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEach molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action\u003c\/li\u003e \u003cli\u003eMutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent\u003c\/li\u003e \u003cli\u003eHistory of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer\u003c\/li\u003e \u003cli\u003eThe discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eCombining the most significant recent discoveries in a unique and useful way, \u003ci\u003eMolecules Engineered Against Oncogenic Proteins and Cancer\u003c\/i\u003e is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology as well as for those at industrial companies involved in therapeutic discovery.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAbout the Author\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eE.J. Corey\u003c\/b\u003e has been a Professor at Harvard University since 1959. He was educated at The Massachusetts Institute of Technology (1945-1950) and served as a faculty member at the University of Illinois from 1951 to 1959. He is the 1990 Nobel Laureate in Chemistry. He has received many international awards including the U.S. National Medal of Science, the Japan Prize, the Wolf Prize and the Priestley Medal of the American Chemical Society, and many honorary degrees including DSc degrees from Oxford and Cambridge. He is a member of the U.S. National Academy of Sciences and the U.S. National Academy of Medicine. Professor Corey is the author of more than 1,000 publications and is one of the most cited authors in science. Among his previous books are \u003ci\u003eThe Logic of Chemical Synthesis\u003c\/i\u003e (1989), \u003ci\u003eMolecules and Medicine\u003c\/i\u003e (2007) and \u003ci\u003eEnantioselective Chemical Synthesis\u003c\/i\u003e (2010). \u003c\/p\u003e\u003cp\u003e\u003cb\u003eYong-Jin Wu\u003c\/b\u003e is a medicinal chemist in the pharmaceutical industry with over 25 years of industry experience. He received his B.Sc. in chemistry from Hunan Normal University (Changsha, China) in 1983 and his Ph.D. in organic chemistry from Memorial University of Newfoundland in 1991 under Professor Jean Burnell. Subsequently, he undertook postdoctoral training in natural product synthesis with Professor Derrick Clive at the University of Alberta (1991-1992) and Professor E. J. Corey at Harvard University (1992-1995). He started his career as a medicinal chemist at Pfizer Central Research in Groton, CT in 1995 and joined Bristol Myers Squibb (BMS) in Wallingford, CT in 1999. He has been working at BMS ever since and currently is at the Cambridge, MA facility where his investigations focus on the discovery of novel kinase inhibitors for immunology, rheumatology and oncology indications.\u003cbr\u003e\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":50394203259154,"sku":"9781394207084","price":150.99,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0831\/4771\/8930\/files\/img_5312951d-bd21-4ad7-a5a1-4aceaf1e847d.jpg?v=1728999283","url":"https:\/\/surprise-castle.myshopify.com\/products\/molecules-engineered-against-oncogenic-proteins-and-cancer-discovery-design-and-development-9781394207084","provider":"Surprise Castle","version":"1.0","type":"link"}